Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
13.30
+0.01 (0.04%)
Nov 21, 2024, 11:48 AM EST - Market open
Takeda Pharmaceutical Revenue
Takeda Pharmaceutical had revenue of 1.18T JPY in the quarter ending September 30, 2024, with 12.75% growth. This brings the company's revenue in the last twelve months to 4.55T, up 9.43% year-over-year. In the fiscal year ending March 31, 2024, Takeda Pharmaceutical had annual revenue of 4.26T with 5.87% growth.
Revenue (ttm)
4,546.08B JPY
Revenue Growth
+9.43%
P/S Ratio
n/a
Revenue / Employee
92,248,189 JPY
Employees
49,281
Market Cap
42.05B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
Mar 31, 2020 | 3,291.19B | 1,193.96B | 56.93% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CVS Health | 367.25B |
McKesson | 330.19B |
Cencora | 293.96B |
GSK | 41.97B |
Becton, Dickinson and Company | 19.83B |
GE HealthCare Technologies | 19.56B |
Haleon | 15.07B |
Alcon | 9.76B |
TAK News
- 1 day ago - Alloy Therapeutics Signs Collaboration and License Agreement with Takeda to Develop Cell Therapy Platform - Business Wire
- 20 days ago - Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 21 days ago - Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments - Reuters
- 21 days ago - Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook - Business Wire
- 4 weeks ago - Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem - Business Wire
- 6 weeks ago - Takeda Pharmaceuticals: An Interesting Option For Income Investors - Seeking Alpha
- 2 months ago - Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development - Business Wire
- 2 months ago - Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer - Business Wire